Overview
- Ventyx shares jumped 62.5% after hours to $16.34 following a Wall Street Journal report of advanced talks with Eli Lilly.
- Trading in Ventyx was temporarily halted during regular hours due to volatility tied to the takeover speculation.
- A deal valuing Ventyx above $1 billion would be roughly double its market capitalization before the report.
- Ventyx develops oral therapies targeting the NLRP3 inflammatory pathway, including programs for Crohn's disease and rheumatoid arthritis plus a mid‑stage candidate for obesity‑related cardiovascular disease.
- Jefferies notes broad pharma interest in NLRP3 from companies like Roche and Novo Nordisk, with a potential Lilly deal seen as expanding its autoimmune and obesity portfolio while both parties declined to comment and a formal announcement could come soon.